Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 31, 2024
Daily News
May 31, 2024
- Finance Minister Acknowledges Wholesalers’ Plight with Frequent Drug Price Revisions
May 31, 2024
- Nitrosamine Guideline to Be Proposed as New Topic for ICH at Fukuoka Confab
May 31, 2024
- Moderna Submits RSV Vaccine in Japan
May 31, 2024
- Nxera Gets US$4.6 Million Milestone over Centessa’s OX2R Agonist
May 31, 2024
- Expand Mixed-Billing Scheme to Cover Gene Panel Test: LDP Committee Proposal
May 31, 2024
- Viatris Launches Cystadrops, Its 1st Brand-Name Product in Japan
May 31, 2024
- Takeda’s cTTP Drug Adzynma Now Available in Japan
May 31, 2024
- How to Plan for Future Talent Needs
May 31, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…